Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease

NCT ID: NCT06817434

Last Updated: 2025-02-10

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 330 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-12-15
• Study Completion Date: 2026-12-31

Brief Summary

The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.

Conditions

Moyamoya Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Revascularization/Conservative management

Revascularization/Conservative management

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The imaging examination meets the diagnostic criteria for moyamoya disease;

2. Sign the informed consent form;

3. Age ≥18 years old;

4. Baseline mRS score ≤2 points;

5. The patient receives revascularization/conservative treatment;

6. There is at least 1 imaging follow-up result.

Exclusion Criteria

1. Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome;

2. Individuals under the age of 18;

3. Participants who refuse to take part in this study;

4. Pregnant patients;

5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus;

6. A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease;

7. Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation;

8. Allergies to contrast media;

9. Patients with missing imaging data or whose image quality cannot be analyzed;

10. Individuals who refuse or are unable to undergo imaging follow-up;

11. Patients receiving other types of lipid-lowering drug treatments.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Tiantan Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Tiantan Hospital

Beijing, China, China

Site Status: RECRUITING

Countries

China

Central Contacts

Qian Zhang

Role: CONTACT

zhangqianchina@yahoo.com

8613120012579

Chaofan Zeng

Role: CONTACT

zchf723@163.com

8613693276138

Facility Contacts

Qian Zhang, MD

Role: primary

zhangqianchina@yahoo.com

8613120012579

Other Identifiers

KY2023-297-02

Identifier Type: -

Identifier Source: org_study_id